Loading...
No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects
Background: Patients receiving the multikinase inhibitor sorafenib for locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine often receive concomitant levothyroxine for thyrotropin (TSH) suppression. In the Phase 3 DTC trial (DECISION),...
Na minha lista:
| Udgivet i: | Thyroid |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Mary Ann Liebert, Inc.
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5646750/ https://ncbi.nlm.nih.gov/pubmed/28741453 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/thy.2017.0085 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|